Table 3.
Mediation Analysis Results Considering the Presence of Coronary Calcium and Coronary Plaque
| Proteins | Direct Effect of ASCVD | Indirect Effect of ASCVD | |||||
|---|---|---|---|---|---|---|---|
| OR | (95% CI) | P | OR | (95% CI) | P | Proportion Mediated, % | |
| Presence of coronary calcium | |||||||
| TNFSF13B | 1.024 | (1.017–1.030) | <.0001 | 1.001 | (1.000–1.002) | .084 | 2.600 |
| LTBR | 1.024 | (1.017–1.030) | <.0001 | 1.001 | (1.000–1.002) | .088 | 2.740 |
| IL-18BP | 1.024 | (1.017–1.029) | <.0001 | 1.001 | (1.000–1.003) | .016 | 4.650 |
| TNF-R1 | 1.023 | (1.016–1.029) | <.0001 | 1.001 | (1.000–1.003) | .002 | 5.711 |
| IGFBP-7 | 1.022 | (1.015–1.028) | <.0001 | 1.002 | (1.001–1.005) | .002 | 9.396 |
| PLC | 1.023 | (1.017–1.029) | <.0001 | 1.001 | (1.000–1.003) | .024 | 4.844 |
| NCR1 | 1.026 | (1.020–1.032) | <.0001 | 0.999 | (.997–1.000) | .010 | −5.476 |
| PGF | 1.023 | (1.016–1.029) | <.0001 | 1.002 | (1.001–1.004) | .004 | 8.225 |
| TNFRSF4 | 1.025 | (1.018–1.030) | <.0001 | 1.000 | (.999–1.001) | .694 | −0.639 |
| CST3 | 1.023 | (1.015–1.029) | <.0001 | 1.002 | (1.000–1.004) | .012 | 7.501 |
| VCAM1 | 1.025 | (1.018–1.031) | <.0001 | 1.000 | (.998–1.001) | .642 | −0.993 |
| NRP1 | 1.024 | (1.017–1.029) | <.0001 | 1.001 | (1.000–1.003) | .128 | 4.381 |
| AOC3 | 1.025 | (1.018–1.031) | <.0001 | 0.999 | (.998–1.001) | .376 | −1.876 |
| OSMR | 1.025 | (1.018–1.030) | <.0001 | 1.000 | (.999–1.001) | .782 | 0.597 |
| DCN | 1.023 | (1.016–1.029) | <.0001 | 1.001 | (1.000–1.003) | .016 | 5.527 |
| GDF-15 | 1.021 | (1.014–1.027) | <.0001 | 1.003 | (1.001–1.006) | .002 | 12.578 |
| REG1A | 1.024 | (1.018–1.030) | <.0001 | 1.001 | (.999–1.002) | .290 | 2.112 |
| ST2 | 1.023 | (1.016–1.029) | <.0001 | 1.001 | (1.000–1.003) | .018 | 5.224 |
| SERPINA5 | 1.024 | (1.018–1.030) | <.0001 | 1.000 | (1.000–1.001) | .358 | 1.102 |
| CCL24 | 1.025 | (1.019–1.030) | <.0001 | 1.000 | (.998–1.001) | .778 | −0.656 |
| IL-6RA | 1.026 | (1.019–1.032) | <.0001 | 0.999 | (.998–1.000) | .094 | −3.559 |
| CCL23 | 1.025 | (1.018–1.031) | <.0001 | 1.000 | (.999–1.001) | .968 | −0.084 |
| MEPE | 1.025 | (1.019–1.031) | <.0001 | 0.999 | (.998–1.000) | .098 | −2.786 |
| Presence of coronary plaque | |||||||
| TNFSF13B | 1.031 | (1.021–1.040) | <.0001 | 1.001 | (1.000–1.003) | .064 | 3.305 |
| LTBR | 1.032 | (1.021–1.041) | <.0001 | 1.001 | (1.000–1.003) | .082 | 3.576 |
| IL-18BP | 1.031 | (1.021–1.040) | <.0001 | 1.002 | (1.000–1.004) | .016 | 4.685 |
| TNF-R1 | 1.030 | (1.020–1.040) | <.0001 | 1.002 | (1.001–1.004) | .002 | 6.763 |
| IGFBP-7 | 1.029 | (1.018–1.039) | <.0001 | 1.003 | (1.001–1.006) | <.0001 | 9.519 |
| PLC | 1.031 | (1.021–1.040) | <.0001 | 1.002 | (1.001–1.004) | <.0001 | 5.944 |
| NCR1 | 1.035 | (1.024–1.043) | <.0001 | 0.998 | (.997–1.000) | .010 | −4.416 |
| PGF | 1.029 | (1.019–1.038) | <.0001 | 1.003 | (1.001–1.006) | <.0001 | 10.291 |
| TNFRSF4 | 1.033 | (1.023–1.042) | <.0001 | 1.000 | (.998–1.001) | .694 | −0.724 |
| CST3 | 1.030 | (1.019–1.039) | <.0001 | 1.003 | (1.001–1.005) | <.0001 | 8.152 |
| VCAM1 | 1.033 | (1.022–1.042) | <.0001 | 1.000 | (.999–1.001) | .674 | −0.512 |
| NRP1 | 1.032 | (1.021–1.041) | <.0001 | 1.001 | (1.000–1.003) | .144 | 2.777 |
| AOC3 | 1.033 | (1.022–1.043) | <.0001 | 0.999 | (.998–1.001) | .376 | −1.704 |
| OSMR | 1.033 | (1.022–1.042) | <.0001 | 1.000 | (.999–1.001) | .786 | 0.370 |
| DCN | 1.031 | (1.021–1.040) | <.0001 | 1.002 | (1.000–1.003) | .028 | 4.473 |
| GDF-15 | 1.029 | (1.018–1.038) | <.0001 | 1.003 | (1.001–1.006) | .008 | 10.315 |
| REG1A | 1.032 | (1.022–1.041) | <.0001 | 1.001 | (.999–1.002) | .296 | 1.777 |
| ST2 | 1.031 | (1.020–1.041) | <.0001 | 1.001 | (1.000–1.003) | .030 | 3.917 |
| SERPINA5 | 1.032 | (1.022–1.041) | <.0001 | 1.001 | (.999–1.002) | .314 | 1.896 |
| CCL24 | 1.033 | (1.023–1.041) | <.0001 | 1.000 | (.998–1.001) | .782 | −0.454 |
| IL-6RA | 1.034 | (1.023–1.043) | <.0001 | 0.999 | (.997–1.000) | .100 | −2.679 |
| CCL23 | 1.033 | (1.023–1.042) | <.0001 | 1.000 | (.998–1.002) | .968 | −0.085 |
| MEPE | 1.035 | (1.025–1.043) | <.0001 | 0.998 | (.996–1.000) | .014 | −5.565 |
Proteins that significantly mediate the effects of ASCVD risk are shown in bold.
Abbreviations: ASCVD, atherosclerotic cardiovascular disease; CI, confidence interval; OR, odds ratio.